Heron Bay Capital Management Acquires Shares of 30,284 Medpace Holdings, Inc. $MEDP

Heron Bay Capital Management acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 30,284 shares of the company’s stock, valued at approximately $16,038,000. Medpace accounts for about 1.5% of Heron Bay Capital Management’s portfolio, making the stock its 23rd biggest position. Heron Bay Capital Management owned about 0.11% of Medpace as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. Johnson Financial Group Inc. purchased a new stake in shares of Medpace during the second quarter worth approximately $27,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the fourth quarter worth $30,000. Allied Private Wealth LLC purchased a new position in Medpace in the 2nd quarter valued at $31,000. Kilter Group LLC purchased a new position in Medpace in the 2nd quarter valued at $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Medpace in the 2nd quarter valued at $34,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MEDP. TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Mizuho lifted their target price on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Price Performance

Shares of MEDP stock opened at $620.75 on Friday. The business’s fifty day moving average price is $550.16 and its 200 day moving average price is $492.71. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm has a market capitalization of $17.33 billion, a PE ratio of 36.39, a P/E/G ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 122,261 shares of company stock worth $71,729,129. Insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.